Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial

Терапевтический архив

Mikhail B. Antsiferov¹  Gagik R. Galstyan²  Albert S. Galyavich³  Niaz R. Khasanov³  Iurii Sh. Khalimov⁴  Vladimir V. Salukhov⁴  Dmitriy V. Cherkashin⁴  Fail T. Ageev⁵  Sergey N. Tereshchenko⁵  Sergey S. Yakushin⁶  Gregory P. Arutyunov⁷  Anastasiya Iu. Lebedeva⁷  Svetlana V. Villevalde⁷  Nadezhda G. Vinogradova⁸  Igor V. Fomin⁸  Ekaterina I. Tarlovskaya⁸  Aleksandr S. Ametov⁹  Sergey R. Gilyarevskiy⁹  Igor V. Zhirov⁹  Maria G. Glezer^1,10  Yuri M. Lopatin^1,11  Sergey M. Nedogoda^1,11  Mikhail V. Ilyin^1,12 

[1] Endocrinology Dispensary;Endocrinology Research Centre;Kazan State Medical University;Kirov Military Medical Academy;National Medical Research Center of Cardiology;Pavlov Ryazan State Medical University;Pirogov Russian National Research Medical University;Privolzhsky Research Medical University;Russian Medical Academy of Continuous Professional Education;Sechenov First Moscow State Medical University (Sechenov University);Volgograd State Medical University;Yaroslavl State Medical University;

关键词: empagliflozin;    chronic heart failure;    hospitalization;    decompensation of chronic heart failure;    cardiovascular mortality;    chronic kidney disease;    emperor-preserved trial;    emperor-reduced trial;    empa-reg outcome trial;    clinical inertia;   

DOI  :  10.26442/00403660.2021.12.201281

来源: DOAJ

【 摘 要 】

At an international online expert meeting held on September 16, 2021, the results of the empagliflozin research program EMPA-REG Outcome, EMPEROR-Reduced and EMPEROR-Preserved were reviewed. We analyzed cardiovascular and renal outcomes during the treatment with empagliflozin in patients with chronic heart failure, regardless of the presence of type 2 diabetes mellitus. The positive results of the EMPEROR-Preserved study are updated and their significance for clinical practice is discussed. Several proposals have been adopted that will accelerate the introduction of empagliflozin therapy into practice in patients with heart failure and overcome clinical inertia.

【 授权许可】

Unknown